| Trial ID: | L0134 |
| Source ID: | NCT04395950
|
| Associated Drug: |
PF-05221304
|
| Title: |
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
|
| Acronym: |
--
|
| Status: |
Withdrawn
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH (Nonalcoholic Steatohepatitis)|NAFLD (Nonalcoholic Fatty Liver Disease)
|
| Interventions: |
Drug: PF-05221304|Drug: Placebo
|
| Outcome Measures: |
Rate of Secretion (also called production-PR) of VLDL TG (mg/kg/day)|Fractional Clearance Rate (FCR) of VLDL TG (pool/day)
|
| Sponsor/Collaborators: |
Columbia University|Pfizer
|
| Gender: |
All
|
| Age: |
18 Years to 70 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
0
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science
|
| Start Date: |
December 2020
|
| Completion Date: |
August 19, 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
August 25, 2021
|
| Locations: |
--
|
| URL: |
https://ClinicalTrials.gov/show/NCT04395950
|
